Skip to main content
Study compares lymphoma remission rates between obinutuzumab, rituximab

A study on the efficacy of Gazyva, or obinutuzumab, found that the drug was able to curb cancer progression or relapse in 80% of patients with follicular lymphoma three years after treatment compared with approximately 73% of patients taking rituximab, according to findings published in The New England Journal of Medicine. The researchers did note, however, that the Gazyva also produced a greater number of side effects than rituximab.

Full Story: